Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists
J Am Coll Cardiol 2024;84:696-708.ArticlePubMed 83
Thats where GLP-1 steps inits like an extra set of traffic lights, helping keep everything under control
SGLT-2 inhibitors cause robust reduction of HHF and the renal outcome, and moderate reduction of CV or total deaths and MACE [13]
They may help patients eat less without feeling constantly deprived, reduce food noise, improve portion control, and maintain better consistency over time
FDA approved GLP-1 r eceptor a gonists for type 2 diabetes mellitus GLP-1 r eceptor a gonists at BOC Sciences Future t rends in the d evelopment of GLP-1 r eceptor a gonists Looking back at the development of GLP-1 receptor agonists (GLP-1 RAs), two main goals have consistently guided their advancement: improving patient compliance and enhancing product efficacy